Dr. Byung Ha Lee is the Chief Business Officer at Huonslab Co., Ltd., S. Korea, where he leverages his extensive 15+ years of experience in biopharmaceutical R&D to drive strategic growth and commercialization initiatives. A highly accomplished scientific executive, Dr. Lee's expertise spans the full drug development lifecycle, with a primary focus on oncology, immuno-oncology, rare diseases, and immunology.

Previously, as Chief Scientific Officer at NeoImmuneTech, Inc.,he provided executive leadership for the entire R&D engine, ensuring the integration of translational research and biomarker strategies into clinical development plans. Dr. Lee is highly skilled in establishing and managing strategic collaborations with major pharmaceutical companies (including Merck, BMS, Roche), Key Opinion Leaders (KOLs), and academic institutions, a capability honed through his previous roles at Genexine and Samsung Biomedical Research Institute, where he also led successful business development initiatives.

Dr. Lee holds a Ph.D. in Biomedical Sciences (immunology and microbiology) from the University of Florida, complemented by postdoctoral training at the National Institutes of Health (NIH), USA. He is a data-driven leader with a proven track record of converting scientific innovation into commercial opportunities and building value through strategic alliances.

Beyond his corporate roles, Dr. Lee has actively contributed to the broader scientific community, serving as 2nd President (2021-2024) of the Korean American Professional Association in Life Sciences (KAPAL) and as an expert panel member (2018-present) for the American Society of Clinical Oncology (ASCO) Educational Book. Dr. Lee is a data-driven, results-oriented leader adept at navigating complex challenges, managing resources effectively, and translating innovative science into meaningful therapeutic advancements and strategic business opportunities for Huonslab.